ArticleDiscover oncology2026
Sustained improvement in survival for primary ocular adnexal lymphoma from 2005 to 2024 by model-based period analysis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposePrimary ocular adnexal lymphoma (POAL) is the most common malignancy affecting para-ocular tissues, making prognosis and survival critical concerns. This study analyzed trends in five-year relative survival rates (RSR) to evaluate survival outcomes.
methodsThis retrospective study included patients diagnosed with POAL from the Surveillance, Epidemiology, and End Results database. Five-year RSR was calculated for the periods 2005-2009, 2010-2014, and 2015-2019. Data were stratified by demographic and clinical characteristics. Model-based period analysis was conducted to assess RSR trends and project RSR for 2020-2024.
resultsThe five-year RSR for POAL patients increased from 96.1% to 99.1% between 2005 and 2019, with projections suggesting continued favorable trends. RSR decreased with advancing age but improved across all age groups; for 2020-2024, RSR was projected to approach 100% for patients aged < 50 and 50-69 years, and 98.3% for those ≥ 70 years. Females consistently showed slightly higher RSR than males. White patients demonstrated steady improvement, while Black patients exhibited a fluctuating trend and other racial groups showed modest increases. Higher RSR was observed in patients with conjunctival involvement, unilateral disease, and mucosal-associated lymphoid tissue (MALT) or follicular lymphoma subtypes.
conclusionSurvival for POAL patients improved between 2005 and 2019. Projected estimates for 2020-2024, while subject to inherent uncertainty, suggest continued favorable outcomes, providing useful prognostic information for clinicians and patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.